Evidence map›Paper›PMID 31161586›Full record

ArticlePharmacoEconomics2019

Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.

Dominik Golicki, Michał Jakubczyk, Katarzyna Graczyk, Maciej Niewada

Abstract read
In one paragraph

Article in PharmacoEconomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Cost-Effectiveness of Personalised Nutrition in Adults With Overweight and Obesity: PREVENTOMICS Studies in Poland and the UK.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025
    Trial
  7. Trial
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Eliciting discounting model and direction at the individual level with time trade-off follow-up questions.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  13. Article
  14. The value of social robots supporting informal care: a discrete choice experiment among informal caregivers.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  15. Comparing EQ-5D-5L and SF-6Dv2 utilities with QLU-C10D utilities in hematologic cancer patients.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  16. Article
  17. Article
  18. A Head-On Comparison of EQ-VT- and Crosswalk-Based EQ-5D-5L Value Sets.Applied health economics and health policy · 2025
    Article
  19. Valuing health-related quality of life: an EQ-5D-5L value set for Morocco.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dominik GolickiDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1b St., 02-097, Warsaw, Poland. dominik.golicki@wum.edu.pl.ORCID 0000-0001-7741-4760
Michał JakubczykDecision Analysis and Support Unit, SGH Warsaw School of Economics, Al. Niepodległości 162, 02-554, Warsaw, Poland.ORCID 0000-0002-0006-6769
Katarzyna GraczykHealthQuest Spółka z ograniczoną odpowiedzialnością Sp. k., 63 Mickiewicza Street, Megadex A Building, 01-625, Warsaw, Poland.
Maciej NiewadaDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1b St., 02-097, Warsaw, Poland.ORCID 0000-0002-3730-1996

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCost-utility analyses are becoming increasingly important in Central and Eastern Europe. We aimed to develop a Polish utility tariff for EQ-5D-5L health states.

methodsFace-to-face, computer-assisted interviews were collected in a representative sample. Each respondent followed a standardised protocol to collect ten composite time trade-off and seven discrete choice experiment observations. In the Bayesian approach, several model specifications were compared based on model fit, the usability of the final value set and how they reflect the elicitation procedure (e.g. censoring). A hybrid approach (using composite time trade-off and discrete choice experiment data) was employed in the final set, which was compared with the existing ones: EQ-5D-3L and EQ-5D-5L cross-walk.

resultsData from 1252 respondents (11,480 composite time trade-off valuations and 8764 discrete choice experiment pairs) were collected over the period June to October 2016. The final model accounted for random parameters, error scaling with fat tails, censoring at - 1, unwillingness to trade in time trade-off by the religious people and Cauchy distribution in discrete choice experiments. Pain/discomfort impacts the utility most: the disutility equals 0.575 when at level 5. In the value set, 4.4% of EQ-5D-5L states are worse than dead. The new value set has a comparable range (minimum of - 0.590 compared to - 0.523) and the same ordering of the first three dimensions (pain/discomfort, mobility, self-care) as the EQ-5D-3L value set and the EQ-5D-5L cross-walk value set. Moreover, it is more sensitive to a moderate decline in health.

conclusionsThe new value set supports consistency with past decisions in cost-utility studies, while offering a better assessment of even moderate improvements in health. It could represent an option for Central and Eastern Europe countries lacking their own value sets.

Indexed as

Health StatusQuality-Adjusted Life YearsQuality of LifeSurveys and QuestionnairesAdolescentAdultAgedAged, 80 and overBayes TheoremCost-Benefit AnalysisDecision MakingFemaleHumansInterviews as TopicMaleMiddle Aged

Identifiers

PMID31161586
PMCPMC6830402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.